Ignota Labs features in Real Deal's piece on how investors are thinking about biotech and early stage drug discovery.
Our CEO Sam Windsor talks about why biotech investing can look very different from traditional private equity. As he says: "It is going to boil down to the return profile. A PE firm might make five investments and success means that they make 2x on one of them and failure is that it just holds its value. But in biotech, success is that you have 100x-ed it, and failure is it went to zero.”
The feature also highlights the high cost of drug failures and the importance of improving conversion rates. At Ignota, we focus on rescuing drugs that fail during clinical trials by using our AI platform SAFEPATH to understand their safety issues.
Read more:
'Capital injection,' can be read in full at Real Deals.
Published 17 November 2025 by Real Deals.
